Neoprobe tests radiotracer in melanoma trial:
This article was originally published in Clinica
Neoprobe is to begin a US clinical trial of its investigational lymphatic radiotracer in melanoma patients. The study, supported by a $250,000 grant from the American Cancer Society, will evaluate use of the agent Tc-mannosyl-dextran as a means of identifying the sentinel lymph node in patients with the disease. The accurate determination of the spread of disease into the lymphatic system is important in establishing the appropriate type of treatment, says the Dublin, Ohio firm. A study assessing use of the agent in the treatment of breast cancer is already underway in the US.